Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,045
  • Shares Outstanding, K 60,181
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,210 K
  • EBIT $ -36 M
  • EBITDA $ -36 M
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.97
  • Most Recent Earnings $-0.37 on 11/08/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 1
  • High Estimate -0.35
  • Low Estimate -0.35
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +75.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1700 +47.47%
on 12/19/24
0.3895 -35.64%
on 12/20/24
+0.0727 (+40.84%)
since 11/26/24
3-Month
0.1300 +92.85%
on 11/22/24
0.4200 -40.31%
on 09/27/24
-0.1494 (-37.34%)
since 09/26/24
52-Week
0.1300 +92.85%
on 11/22/24
2.6800 -90.65%
on 12/28/23
-2.0543 (-89.12%)
since 12/26/23

Most Recent Stories

More News
Aptose Biosciences Receives Extension from Nasdaq to Demonstrate Compliance with Listing Requirements

Aptose Biosciences receives extension from Nasdaq to comply with listing requirements by March 31, 2025, following recent funding and clinical agreements.Quiver AI SummaryAptose Biosciences Inc. has received...

APTO : 0.2507 (+0.28%)
Aptose Announces Positive Decision by Nasdaq Hearings Panel

APTO : 0.2507 (+0.28%)
APS.TO : 0.3650 (+2.82%)
Aptose Biosciences Announces Publication Detailing Tuspetinib's Mechanism of Action and Promising Results in Acute Myeloid Leukemia Treatment

Aptose announces preclinical findings of tuspetinib in AML treatment, demonstrating efficacy and safety in combination therapies.Quiver AI SummaryAptose Biosciences Inc. announced the publication of preclinical...

APTO : 0.2507 (+0.28%)
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

APTO : 0.2507 (+0.28%)
APS.TO : 0.3650 (+2.82%)
Aptose Biosciences Initiates Enrollment for TUS+VEN+AZA Triplet Therapy in Newly Diagnosed AML Patients

Aptose Biosciences announces enrollment for TUS+VEN+AZA trial, targeting newly diagnosed AML patients with promising safety and efficacy.Quiver AI SummaryAptose Biosciences Inc. has announced the enrollment...

APTO : 0.2507 (+0.28%)
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

APTO : 0.2507 (+0.28%)
APS.TO : 0.3650 (+2.82%)
Aptose Biosciences' Tuspetinib Selected for National Cancer Institute's myeloMATCH Trials Targeting AML and MDS

Tuspetinib is selected for the NCI's myeloMATCH trials to treat AML and MDS with targeted drug combinations.Quiver AI SummaryAptose Biosciences announced that its lead compound, tuspetinib, has been selected...

APTO : 0.2507 (+0.28%)
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

APTO : 0.2507 (+0.28%)
APS.TO : 0.3650 (+2.82%)
Insider Purchase: Chair of $APTO (APTO) Buys 100,000 Shares

William G. Rice, the Chair of $APTO ($APTO), bought 100,000 shares of the company on 11-25-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

APTO : 0.2507 (+0.28%)
Aptose Biosciences Closes $8 Million Public Offering for Oncology Development

Aptose Biosciences closed an $8 million public offering, selling 40 million shares and 20 million warrants for funding.Quiver AI SummaryAptose Biosciences Inc. announced the successful completion of a...

APTO : 0.2507 (+0.28%)

Business Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in...

See More

Key Turning Points

3rd Resistance Point 0.3043
2nd Resistance Point 0.2869
1st Resistance Point 0.2688
Last Price 0.2507
1st Support Level 0.2333
2nd Support Level 0.2159
3rd Support Level 0.1978

See More

52-Week High 2.6800
Fibonacci 61.8% 1.7059
Fibonacci 50% 1.4050
Fibonacci 38.2% 1.1041
Last Price 0.2507
52-Week Low 0.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar